Physician profile
Daniella Munteanu
NPI 1427289438
$3,075.94
in general payments reported to CMS, 2019-2025
19 companies · $634 in 2025
The $634 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $188 · 2021: $324 · 2022: $636 · 2023: $447 · 2024: $592 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $812.11 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $551.26 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $421.03 | 2021-2025 | |
| Pfizer INC. | $367.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $185.43 | 2020-2025 | Eliquis |
| La Jolla Pharmaceutical Company | $118.09 | 2023-2025 | Xerava, Zevtera, Xacduro |
| Melinta Therapeutics, LLC | $112.16 | 2024-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Gilead Sciences, INC. | $110.13 | 2023-2024 | |
| Shionogi INC | $87.40 | 2022-2025 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.05 | 2022-2025 | Jardiance |
| Cumberland Pharmaceuticals, INC. | $48.25 | 2022-2025 | Caldolor |
| Paratek Pharmaceuticals, INC. | $42.21 | 2025 | Nuzyra |
| Insmed, INC. | $30.22 | 2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $25.12 | 2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $24.63 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.06 | 2019-2020 | |
| Lilly USA, LLC | $19.60 | 2019 | |
| Mylan Specialty L.P. | $17.76 | 2020 | |
| Smith+Nephew, INC. | $16.31 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniella Munteanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.